Ascendis Pharma Reports Strong Revenue and Outlines 2026 Milestones at JPM Conference
Ascendis Pharma announced Q4 product revenue of about €240M and full-year revenue of about €683M at the J.P. Morgan Healthcare Conference, highlighting profitability, Yorvipath expansion, and upcoming regulatory decisions.